NASDAQ:SNOA - Sonoma Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.03
▼ -0.28 (-3.37%)
1 month | 3 months | 12 months
Get New Sonoma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNOA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNOA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sonoma Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.03.
N/A
The current consensus among 0 investment analysts is to n/a stock in Sonoma Pharmaceuticals. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2018Maxim GroupReiterated RatingHoldHigh
i
7/20/2018BenchmarkReiterated RatingSpeculative Buy$3.00Medium
i
3/5/2018Maxim GroupDowngradeBuy ➝ Hold$7.00Low
i
Rating by Jason Kolbert at Maxim Group
2/14/2018Maxim GroupReiterated RatingBuy ➝ Buy$11.00 ➝ $7.00Low
i
Rating by Jason Kolbert at Maxim Group
2/8/2018Maxim GroupSet Price TargetBuy$11.00 ➝ $7.00High
i
Rating by Jason Kolbert at Maxim Group
12/28/2017BenchmarkInitiated CoverageSpeculative Buy ➝ Speculative Buy$10.00High
i
11/17/2017Maxim GroupSet Price TargetBuy$11.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/10/2017Maxim GroupBoost Price TargetBuy$10.00 ➝ $11.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/9/2017Maxim GroupSet Price TargetBuy$10.00High
i
Rating by Jason Kolbert at Maxim Group
6/6/2017Maxim GroupReiterated RatingBuy ➝ Buy$9.00 ➝ $10.00Low
i
2/16/2017Maxim GroupReiterated RatingBuy$8.00 ➝ $9.00N/A
i
2/10/2017Maxim GroupBoost Price Target$9.00N/A
i
11/11/2016Maxim GroupSet Price TargetBuy$8.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/1/2016Maxim GroupBoost Price TargetBuy$7.00 ➝ $8.00N/A
i
Rating by jason kolbert at Maxim Group
8/11/2016Maxim GroupReiterated RatingBuy$7.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/17/2016Maxim GroupReiterated RatingBuy$3.00N/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 4/21/2016 forward)
Sonoma Pharmaceuticals logo
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Read More

Today's Range

Now: $8.03
$7.86
$8.28

50 Day Range

MA: $7.81
$6.81
$8.88

52 Week Range

Now: $8.03
$4.60
$19.60

Volume

10,398 shs

Average Volume

267,413 shs

Market Capitalization

$16.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Sonoma Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Sonoma Pharmaceuticals in the last twelve months:
View the latest analyst ratings for SNOA.

What is the current price target for Sonoma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Sonoma Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sonoma Pharmaceuticals in the next year.
View the latest price targets for SNOA.

What is the current consensus analyst rating for Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNOA.

What other companies compete with Sonoma Pharmaceuticals?

How do I contact Sonoma Pharmaceuticals' investor relations team?

Sonoma Pharmaceuticals' physical mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The company's listed phone number is 800-759-9305 and its investor relations email address is [email protected] The official website for Sonoma Pharmaceuticals is www.sonomapharma.com.